Last Updated: October 8, 2026

Etretinate - Generic Drug Details

Name: etretinate Generic Launch, Drug Patent, and Exclusivity Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

What are the generic sources for etretinate and what is the scope of freedom to operate?

Etretinate is the generic ingredient in one branded drug marketed by Roche and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for etretinate

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	71
Clinical Trials:	3
DailyMed Link:	etretinate at DailyMed

Recent Clinical Trials for etretinate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Fundação de Amparo à Pesquisa do Estado de São Paulo	Phase 4
Federal University of São Paulo	Phase 4
M.D. Anderson Cancer Center	Phase 2

See all etretinate clinical trials

Medical Subject Heading (MeSH) Categories for etretinate

Keratolytic Agents

Anatomical Therapeutic Chemical (ATC) Classes for etretinate

D05BB	Retinoids for treatment of psoriasis
D05B	ANTIPSORIATICS FOR SYSTEMIC USE
D05	ANTIPSORIATICS
D	Dermatologicals

US Patents and Regulatory Information for etretinate

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roche	TEGISON	etretinate	CAPSULE;ORAL	019369-001	Sep 30, 1986		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Roche	TEGISON	etretinate	CAPSULE;ORAL	019369-002	Sep 30, 1986		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for etretinate

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Roche	TEGISON	etretinate	CAPSULE;ORAL	019369-001	Sep 30, 1986	4,200,647	⤷ Start Trial
Roche	TEGISON	etretinate	CAPSULE;ORAL	019369-002	Sep 30, 1986	4,200,647	⤷ Start Trial
Roche	TEGISON	etretinate	CAPSULE;ORAL	019369-002	Sep 30, 1986	4,215,215	⤷ Start Trial
Roche	TEGISON	etretinate	CAPSULE;ORAL	019369-001	Sep 30, 1986	4,215,215	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.